Magnesium Supplementation as a Nutritional Intervention in Sarcopenia (SARCOMAG)
5. května 2026 aktualizováno: Dina Raquel Fernandes João, Escola Superior de Saúde - Universidade do Algarve
Effects of Magnesium Supplementation on Muscle Strength, Muscle Mass, and Physical Performance in Sarcopenic Individuals
Sarcopenia is a progressive condition common in older adults and is characterized by loss of muscle strength, muscle mass, and physical performance. It is associated with an increased risk of falls, disability, reduced independence, and poorer quality of life. Nutritional interventions are recommended as part of sarcopenia management; however, evidence regarding the role of specific micronutrients remains limited. Magnesium is an essential mineral involved in muscle contraction, neuromuscular function, energy production, and inflammation regulation. Low magnesium status is frequent in older adults and may contribute to muscle impairment and physical decline.
This study aims to evaluate the effects of magnesium supplementation on muscle strength, muscle mass, and physical performance in older adults with sarcopenia living in the eastern Algarve region of Portugal. In addition, the study will assess the prevalence of low magnesium status and sarcopenia in this population.
The study will be conducted in two phases. In the first, observational phase, community-dwelling adults aged 70 years or older will be assessed for sarcopenia according to established diagnostic criteria. Blood samples will be collected to measure serum and erythrocyte magnesium levels and C-reactive protein as an inflammatory marker. Participants diagnosed with sarcopenia and presenting low magnesium levels will be eligible for the second phase.
In the second phase, eligible participants will be randomly assigned to receive either oral magnesium supplementation (400 mg/day of magnesium citrate) or a placebo for 12 weeks, in a double-blind and controlled design. After the intervention period, participants will be reassessed for muscle strength, muscle mass, physical performance, magnesium status, and inflammation.
The results of this study are expected to clarify the role of magnesium supplementation as a nutritional strategy in sarcopenia. Findings may contribute to improving nutritional recommendations and supporting interventions aimed at preserving muscle health, physical function, and quality of life in older adults.
Přehled studie
Postavení
Zatím nenabíráme
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Odhadovaný)
352
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: Dina F João
- Telefonní číslo: +351961647475
- E-mail: drjoao@ualg.pt
Studijní místa
-
-
Faro District
-
Faro, Faro District, Portugalsko, 8005-139
- Escola Superior de Saúde - Universidade do Algarve
-
Kontakt:
- Dina F João
- Telefonní číslo: +351961647475
- E-mail: drjoao@ualg.pt
-
Vrchní vyšetřovatel:
- Dina F João
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Starší dospělý
Přijímá zdravé dobrovolníky
Ano
Popis
Inclusion Criteria:
- Adults aged 70 years or older
- Community-dwelling individuals residing in the eastern Algarve region of Portugal
- Not hospitalized at the time of recruitment
- Ability to participate in study assessments, regardless of mobility status
- Ability to provide written informed consent, either personally or via a legally authorized representative when applicable
- Adequate cognitive ability to collaborate with study procedures, as determined by screening assessment
Exclusion Criteria:
- Alcoholism
- Acute gastrointestinal conditions with symptoms of diarrhea and/or vomiting
- Presence of conditions associated with magnesium imbalance, including: Electrolyte disorders, Hyperthyroidism, Type 1 diabetes mellitus, Renal disease, Hyperaldosteronism, Short bowel syndrome or history of intestinal resection, Gastric bypass surgery
- Use of medications known to affect magnesium metabolism, including: Loop or thiazide diuretics (e.g., furosemide, thiazides), Proton pump inhibitors (e.g., omeprazole, pantoprazole, esomeprazole), Cytotoxic agents (e.g., cisplatin, carboplatin, gallium nitrate), Antimicrobial agents such as aminoglycosides, Immunosuppressive agents, Beta-adrenergic agonists (e.g., theophylline, salbutamol, rimiterol), Cetuximab, Cyclosporine A, Pamidronate.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Komparátor placeba: Placebo
Participants assigned to the placebo comparator group will receive an oral placebo administered daily for 12 weeks.
The placebo consists of capsules containing microcrystalline cellulose, an inert substance with no known biological effects.
The placebo capsules are identical in appearance, taste, and packaging to the magnesium supplement, ensuring blinding of participants and investigators.
Participants will be instructed to take the capsules according to the same schedule as the intervention group.
Adherence will be monitored through capsule count at follow-up visits.
|
Participants assigned to the placebo comparator arm will receive an oral placebo administered daily for 12 weeks.
The placebo consists of capsules containing microcrystalline cellulose, an inert substance with no known physiological or therapeutic effects.
The placebo capsules are identical in appearance, taste, and packaging to the magnesium supplement to ensure blinding of participants and investigators.
The dosing schedule will be the same as that used in the experimental group.
Adherence to the intervention will be monitored by capsule count at follow-up visits, and participants will be observed regularly for tolerability and safety.
|
|
Experimentální: Magnesium Supplementation
Participants assigned to the experimental arm will receive oral magnesium supplementation administered daily for a period of 12 weeks.
The intervention consists of magnesium citrate capsules providing a total daily dose of 400 mg of elemental magnesium.
The supplement will be taken according to a standardized dosing schedule identical to that of the placebo group.
Magnesium citrate was selected due to its favorable bioavailability.
Participants and investigators will remain blinded to treatment allocation throughout the study.
Adherence to the intervention will be assessed by capsule count at follow-up visits, and participants will be monitored regularly for tolerability and potential adverse events.
|
Participants assigned to the experimental arm will receive oral magnesium supplementation administered daily for 12 weeks.
The intervention consists of magnesium citrate capsules providing a total daily dose of 400 mg of elemental magnesium.
The supplement will be taken according to a standardized dosing schedule identical to that of the placebo group.
Magnesium citrate was selected due to its favorable bioavailability.
Participants, investigators, and outcome assessors will remain blinded to group assignment throughout the study.
Adherence to the intervention will be assessed by capsule count at follow-up visits, and participants will be monitored regularly for tolerability and potential adverse events.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Muscle Strength
Časové okno: Baseline and 12 weeks
|
Change in muscle strength assessed by handgrip strength using a calibrated handgrip dynamometer.
Handgrip strength will be measured in a seated position, with the elbow flexed at 90 degrees, following standardized procedures.
Three measurements will be performed on the non-dominant hand (or dominant hand if necessary), with the highest value recorded.
Muscle strength will be evaluated at baseline and after 12 weeks of intervention.
|
Baseline and 12 weeks
|
|
Muscle Mass
Časové okno: Baseline and 12 weeks
|
Change in muscle mass assessed by bioelectrical impedance analysis, including appendicular muscle mass and muscle mass adjusted for height.
Measurements will be performed at baseline and after 12 weeks of intervention.
|
Baseline and 12 weeks
|
|
Physical Performance
Časové okno: Baseline and 12 weeks
|
Change in physical performance assessed by the 4-meter gait speed test, conducted according to standardized procedures.
Performance will be assessed at baseline and after 12 weeks of intervention.
|
Baseline and 12 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Serum Magnesium Levels
Časové okno: Baseline and 12 weeks
|
Change in serum magnesium concentration measured from blood samples using standard laboratory procedures.
Serum magnesium levels will be assessed at baseline and after 12 weeks of intervention.
|
Baseline and 12 weeks
|
|
Erythrocyte Magnesium Levels
Časové okno: Baseline and 12 weeks
|
Change in intracellular magnesium status assessed by erythrocyte magnesium concentration measured from blood samples using validated laboratory methods.
Measurements will be performed at baseline and after 12 weeks of intervention.
|
Baseline and 12 weeks
|
|
Inflammation
Časové okno: Baseline and 12 weeks
|
Change in systemic inflammation assessed by serum C-reactive protein (CRP) concentration measured using standard laboratory methods.
CRP levels will be evaluated at baseline and after 12 weeks of intervention.
|
Baseline and 12 weeks
|
|
Adherence to Supplementation
Časové okno: Up to 12 weeks
|
Adherence to the prescribed intervention assessed by capsule count, calculated as the proportion of capsules consumed during the 12-week intervention period.
|
Up to 12 weeks
|
|
Safety and Tolerability
Časové okno: Up to 12 weeks
|
Occurrence of adverse events and tolerability of magnesium supplementation or placebo assessed through participant reporting and regular monitoring during the intervention period.
|
Up to 12 weeks
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Prevalence of Hypomagnesemia
Časové okno: Baseline
|
Prevalence of low magnesium status determined by serum and/or erythrocyte magnesium concentrations below established reference values at baseline.
|
Baseline
|
|
Prevalence of Sarcopenia
Časové okno: Baseline
|
Prevalence of sarcopenia determined at baseline according to the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria.
|
Baseline
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Odhadovaný)
1. června 2026
Primární dokončení (Odhadovaný)
31. ledna 2027
Dokončení studie (Odhadovaný)
30. června 2027
Termíny zápisu do studia
První předloženo
29. dubna 2026
První předloženo, které splnilo kritéria kontroly kvality
29. dubna 2026
První zveřejněno (Aktuální)
5. května 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
8. května 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
5. května 2026
Naposledy ověřeno
1. května 2026
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- UAIF201/2025FARO
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NEROZHODNÝ
Popis plánu IPD
Individual participant data will not be shared due to ethical and data protection constraints.
The study involves an older population considered potentially vulnerable, and informed consent for participation did not include consent for data sharing beyond the research team.
In addition, the risk of re-identification cannot be fully excluded given the detailed clinical and contextual data collected.
Data will be used exclusively for the purposes defined in the approved protocol and in accordance with applicable data protection regulations.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Sarkopenie
-
Ankara Etlik City HospitalDokončenoEndometriální rakovina | Rakovina vaječníků (OvCa) | Rakovina vejcovodů | Chemoterapie indukovaná změna chuti | Podvýživa spojená s rakovinou | Sarcopeni spojené s rakovinouTurecko (Türkiye)